Expert Review of Anticancer Therapy Special Article Collection
Free to Access until 31st December 2020
The Expert Review of Anticancer Therapy is excited to announce a special free-to-view article collection celebrating some of the journal's fantastic contributions from top authors. The collection includes a range of .......
The Expert Review of Anticancer therapy is part of our Expert Collection, the world’s largest series of review journals in research, development and clinical medicine. Comprised of 28 peer-reviewed titles across two series, Expert Opinion & Expert Review, read by thousands of researchers and physicians world-wide, authors can reap the benefits of the collection’s visibility and high impact.
The below articles are free to read exclusively through this page until December 31st, 2020.
|Article Title||Author(s)||Issue Year|
|Current and future therapeutic approaches for osteosarcoma||Douglas J. Harrison, David S. Geller, Jonathan D. Gill, Valerae O. Lewis & Richard Gorlick||2018|
|Targeted therapies in non-small-cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors||Assunta Sgambato, Francesca Casaluce, Paolo Maione & Cesare Gridelli||2018|
|Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer||Misako Nagasaka & Shirish M. Gadgeel||2018|
|Current and future immunotherapies for thyroid cancer||Alessandro Antonelli, Silvia Martina Ferrari & Poupak Fallahi||2018|
|Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer||Howard A. Burris III||2018|
|Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia||Allison Barz, Caitlin W. Elgarten, Stephan A. Grupp, Shannon L. Maude & David T. Teachey||2018|
|Targeted therapy for metastatic colorectal cancer||Timothy J. Price, Monica Tang, Peter Gibbs, Daniel G. Haller, Marc Peeters, Dirk Arnold, Eva Segelov, Amitesh Roy, Niall Tebbutt, Nick Pavlakis, Chris Karapetis, Matthew Burge & Jeremy Shapiro||2018|
|Nivolumab for the treatment of hepatocellular carcinoma||Fabian Finkelmeier, Oliver Waidmann & Joerg Trojan||2018|
|Larotrectinib for the treatment of TRK fusion solid tumors||Theodore W. Laetsch & Douglas S. Hawkins||2019|
|Sorafenib: key lessons from over 10 years of experience||Bernard Escudier, Francis Worden & Masatoshi Kudo||2019|
|Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors||Amro Elshoury, Amanda Przespolewski, Jeffrey Baron & Eunice S. Wang||2019|
|Anti-BCMA antibodies in the future management of multiple myeloma||Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Meletios Athanasios Dimopoulos & Evangelos Terpos||2019|
|Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled||Jan Philipp Bewersdor, Maximilian Stahl & Amer M. Zeidan||2019|
|Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine||Robin Van Den Borg, Alessandro Leonetti, Marcello Tiseo, Elisa Giovannetti & Godefridus J. Peters||2019|
|Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology||Gabriele Di Sante, Jessica Pagé, Xuanmao Jiao, Omar Nawab, Massimo Cristofanilli, Emmanuel Skordalakes & Richard G Pestell||2019|
|Capmatinib for the treatment of non-small-cell lung cancer||Johan Filip VansteenkisteORCID Icon,Charlotte Van De Kerkhove,Els Wauters &Pierre Van Mol||2019|
|The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib||Christopher P Wilding, Mark L Elms, Ian Judson, Aik-Choon Tan, Robin L Jones & Paul H Huang||2019|
|Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies||Lingaku Lee, Tetsuhide Ito & Robert T Jensen||2019|
|The prognostic role of circulating tumor cells in colorectal cancer||Lahiri Kanth Nanduri, Barbara Hissa, Jürgen Weitz, Sebastian Schölch & Ulrich Bork||2019|
Stay ahead of the competition
With Accelerated Publication
If time is critical in your publishing strategy, our Accelerated Publication options can help you get your research into the Expert Review of Anticancer Therapy fast.
Choose accelerated publication to:
- coordinate your publishing schedule with conferences, drug approvals, and drug launches,
- keep competitive advantage by getting your discoveries to market quickly,
- speed up the peer review process without sacrificing quality or rigour.
With articles published as quickly as 3 weeks from submission, our accelerated publication option is the fastest way to publish. Our expert editorial team are here to help if you have any questions or would like pre-submission guidance.
Publish Open Access
In the Expert Review of Anticancer Therapy
Open Access provides you with the following great benefits:
- Immediate access to your article on publication, accessible by anyone, anywhere
- High visibility and discoverability via Taylor & Francis Online
- Input from, and dialog with, expert editors
- Rigorous peer review for every Open Access article
- Metrics (downloads, citations, and Altmetric data) for your article, so you can measure its impact